ILLUMINATE-B, a Phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1)

Speaker(s):

• Kyoungwha Bae, PhD
• Debbie Barrera, BSN
• Pierre Cochat, MD
• Georges Deschenes, MD
• Yaacov Frishberg, MD
• Kenji Fujita, MD
• Pushkal Garg, MD
• Wesley Hayes, MD
• Daniella Magen, MD
• Tracy McGregor, MD
• Mini Michael, MD
• David Sas, MD
• Hadas Sasha-Lavsky, MD
• Gesa Schalk, MD
• Ali Seddighzadeh, MD
• Akshay Vaishnaw, MD
• William VantHoff, MD